|
|
Saccharomyces cerevisiae vaccine vector |
|
Vaxvec ID |
76 |
|
Vaccine Vector Name |
Saccharomyces cerevisiae vaccine vector |
|
Vector VO ID |
VO_0001122
|
|
Advantage |
In addition to the safety profile, there are several advantages of yeast expression systems: high expression levels, ease of scale-up, low cost, and adjuvant potential of yeast cell-wall components, such as β-1,3-d-glucan and mannan. Yeast-based expression systems have been developed and successfully used to produce recombinant proteins. Furthermore cell-surface display in yeast, designed as an antigen delivery system, provide the stable maintenance of surface-expressed epitopes with a high-density displayed protein (Shin et al., 2013). |
|
Safety |
Baker's yeast (Saccharomyces cerevisiae) has been used for the oral application of vaccines and drugs, as a Generally Recognized as Safe (GRAS) organism, because it is relatively stable and nonpathogenic in the gut compared with the other biodegradable vehicles (Shin et al., 2013). |
| Related Vaccine(s) |
|
| References |
Shin et al., 2013: Shin MK, Kang ML, Jung MH, Cha SB, Lee WJ, Kim JM, Kim DH, Yoo HS. Induction of protective immune responses against challenge of Actinobacillus pleuropneumoniae by oral administration with Saccharomyces cerevisiae expressing Apx toxins in pigs. Veterinary immunology and immunopathology. 2013; 151(1-2); 132-139. [PubMed: 23206402].
|
|
